Peter R. Galle

机构：Johannes Gutenberg University Mainz, University Medical Center of the Johannes Gutenberg University Mainz · ORCID：0000-0003-1967-0621

发表论文 56 篇 · 总被引 791 次 · h-index 11

代表论文

• Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial (2025 · The Lancet · 被引 314)
• Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab (2024 · JHEP Reports · 被引 18)
• Inflammation in liver fibrosis and atrial fibrillation: A prospective population-based proteomic study (2024 · JHEP Reports · 被引 16)
• 965MO Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC): Expanded analyses from CheckMate 9DW (2024 · Annals of Oncology · 被引 11)
• Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab (2024 · JHEP Reports · 被引 10)
• Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence (2025 · JHEP Reports · 被引 9)